Characteristics of the 425 eligible patients
. | Without quinine, N = 212 . | With quinine, N = 213 . | P . |
|---|---|---|---|
| Mean age, y | 41 | 41 | NS |
| Sex, n, M/F | 102/110 | 108/105 | NS |
| PS greater than 1, n | 45 | 52 | NS |
| Hemoglobin level, mean g/L | 91 | 90 | NS |
| Leukocyte count, mean G/L | 70.0 | 59.5 | NS |
| Platelet count, mean G/L | 14.4 | 12.0 | NS |
| FAB, n, 0/1/2/4/5/6 | 8/53/67/43/34/7 | 12/53/77/38/28/11 | NS |
| Cytogenetic analysis, n | |||
| Good | 32 | 32 | .01 |
| Intermediate | 112 | 128 | .01 |
| Poor | 39 | 20 | .01 |
| Normal | 80 | 100 | .01 |
| ND/failure | 30 | 37 | .01 |
| MDR phenotype, n | |||
| mdrl gene+ (%) | 36 of 132 (27.3) | 40 of 132 (30.3) | NS |
| 4 E3+ (%) | 30 of 122 (24.6) | 32 of 119 (26.9) | NS |
| UIC2+ (%) | 38 of 126 (30.2) | 39 of 111 (35.1) | NS |
| Rh123 efflux+ (%) | 25 of 78 (32) | 29 of 82 (35.4) | NS |
. | Without quinine, N = 212 . | With quinine, N = 213 . | P . |
|---|---|---|---|
| Mean age, y | 41 | 41 | NS |
| Sex, n, M/F | 102/110 | 108/105 | NS |
| PS greater than 1, n | 45 | 52 | NS |
| Hemoglobin level, mean g/L | 91 | 90 | NS |
| Leukocyte count, mean G/L | 70.0 | 59.5 | NS |
| Platelet count, mean G/L | 14.4 | 12.0 | NS |
| FAB, n, 0/1/2/4/5/6 | 8/53/67/43/34/7 | 12/53/77/38/28/11 | NS |
| Cytogenetic analysis, n | |||
| Good | 32 | 32 | .01 |
| Intermediate | 112 | 128 | .01 |
| Poor | 39 | 20 | .01 |
| Normal | 80 | 100 | .01 |
| ND/failure | 30 | 37 | .01 |
| MDR phenotype, n | |||
| mdrl gene+ (%) | 36 of 132 (27.3) | 40 of 132 (30.3) | NS |
| 4 E3+ (%) | 30 of 122 (24.6) | 32 of 119 (26.9) | NS |
| UIC2+ (%) | 38 of 126 (30.2) | 39 of 111 (35.1) | NS |
| Rh123 efflux+ (%) | 25 of 78 (32) | 29 of 82 (35.4) | NS |
PS indicates performance status; Rh123, rhodamine 123; NS, not significant; and ND, not done.